This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brenner, B. Articles by Marder, V. J. Search for Related Content PubMed PubMed Citation Articles by Brenner, B. Articles by Marder, V. J.

Circulation, Vol 81, 1818-1825, Copyright © 1990 by American Heart Association

ARTICLES

Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation

B Brenner, CW Francis, S Totterman, CM Kessler, AK Rao, R Rubin, HC Kwaan, KR Gabriel and VJ Marder
Department of Medicine, University of Rochester School of Medicine, NY.

Plasma cross-linked fibrin-degradation products were analyzed using a D- dimer (DD) immunoassay in patients with deep vein thrombosis (DVT) or acute myocardial infarction (MI) treated with fibrinolytic therapy, and the results were correlated with clot lysis documented angiographically. In 13 patients with DVT, the mean DD concentration increased 10-fold (1,074 +/- 252 to 10,333 +/- 1,004 ng/ml) during therapy, but neither the peak level nor the DD concentration integrated over the course of therapy correlated with clot lysis. Since plasma DD can derive from degradation of soluble plasma fibrin as well as from thrombi, the contribution of the former was estimated by in vitro incubation of the pretreatment plasma with plasminogen activator. Subtraction of this value from the measured posttreatment DD concentration provided a "corrected" level that represented DD originating from lysis of thrombi. This modification resulted in improved correlation of DD levels with clot lysis. The mean corrected peak DD was higher in patients with successful thrombolysis (8,780 +/- 1,352 ng/ml) compared with patients without lysis (3,075 +/- 589 ng/ml, p less than 0.001). There was a moderate correlation between the volume of clot lysed and the corrected peak DD (r = 0.62) and a higher correlation with the corrected DD integrated over the course of treatment (r = 0.97). By contrast, the corrected DD concentrations were near zero in patients treated for MI with or without thrombolytic reperfusion, suggesting that fibrin in small coronary thrombi did not contribute significantly to total plasma DD during therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S. S. Adam, N. S. Key, and C. S. Greenberg D-dimer antigen: current concepts and future prospects Blood, March 26, 2009; 113(13): 2878 - 2887. [Abstract] [Full Text] [PDF]

				W. L. Chandler, S. Jelacic, D. R. Boster, M. A. Ciol, G. D. Williams, S. L. Watkins, T. Igarashi, and P. I. Tarr Prothrombotic Coagulation Abnormalities Preceding the Hemolytic-Uremic Syndrome N. Engl. J. Med., January 3, 2002; 346(1): 23 - 32. [Abstract] [Full Text] [PDF]

				M.-C. Tataru, J. Heinrich, R. Junker, H. Schulte, A. von Eckardstein, G. Assmann, and E. Koehler D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction Eur. Heart J., October 2, 1999; 20(20): 1493 - 1502. [Abstract] [PDF]

				G. P. Giacoia High-Dose Urokinase Therapy in Newborn Infants with Major Vessel Thrombosis Clinical Pediatrics, April 1, 1993; 32(4): 231 - 237. [Abstract] [PDF]